Regeneron’s Q2 earnings beat expectations

By: Miguel A. Rodriguez

09:45, 14 September 2020

1596631598.jpg
Developing a Coronavirus vaccine has been tremendously beneficial to Regeneron

After Bayer posted its Q2 earnings yesterday, it was the turn of another pharmaceutical company to do the same. The US-based biotechnology company, Regeneron, posted better-than-expected figures.

During the past quarter, the company's net income rose to $897.3 million, or $7.61 per share. It is almost a nine-fold increase from last year's $193.1 million or $1.68/share.

Regeneron’s revenue increased to $1.95 billion from a previous $1.58 billion. It topped the $1.73 billion consensus. The increase in revenue and stock price was due to the collaboration with Sanofi on developing a COVID-19 vaccine. So far, the vaccine looks promising, as it "almost completely blocks establishment of virus infection," when tested on animals, especially on “mice who have been genetically modified to have a human immune system.” The vaccine is currently in clinical trials on humans, and the results are expected to be published later this summer.

After the report, Regeneron's shares were close to a record high, as they ran up 3.2%. Since the beginning of the year, stocks jumped 72.7%, while USA500 added 2.3%.

News, news, news! Read the latest on CAPEX.com!

Sources: marketwatch.com, biospace.com

Share this article

The information presented herein is prepared by CAPEX.com/eu and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only and as such it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.                                                                                                                            Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience, or current financial situation.Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance and forecasts are not reliable indicators of future results.